Mind Other Stockholder Equity from 2010 to 2024

MNMD Stock  USD 8.26  0.15  1.85%   
Mind Medicine's Other Stockholder Equity is increasing over the years with slightly volatile fluctuation. Other Stockholder Equity is expected to dwindle to about 246.9 M. During the period from 2010 to 2024 Mind Medicine Other Stockholder Equity annual values regression line had geometric mean of  5,459,875 and mean square error of 7982.8 T. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2010-12-31
Previous Quarter
368 M
Current Value
246.9 M
Quarterly Volatility
143.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mind Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mind Medicine's main balance sheet or income statement drivers, such as Interest Income of 881.5 K, Interest Expense of 1.8 M or Selling General Administrative of 23.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Mind financial statements analysis is a perfect complement when working with Mind Medicine Valuation or Volatility modules.
  
Check out the analysis of Mind Medicine Correlation against competitors.
For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.

Latest Mind Medicine's Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Mind Medicine over the last few years. It is Mind Medicine's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mind Medicine's overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Mind Other Stockholder Equity Regression Statistics

Arithmetic Mean91,739,701
Geometric Mean5,459,875
Coefficient Of Variation155.94
Mean Deviation121,255,083
Median798,389
Standard Deviation143,063,280
Sample Variance20467.1T
Range367.2M
R-Value0.80
Mean Square Error7982.8T
R-Squared0.64
Significance0.0004
Slope25,548,445
Total Sum of Squares286539.4T

Mind Other Stockholder Equity History

2024246.9 M
2023368 M
2022344.8 M
2021288.3 M
2020120.2 M

About Mind Medicine Financial Statements

Mind Medicine stakeholders use historical fundamental indicators, such as Mind Medicine's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Mind Medicine investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mind Medicine's assets and liabilities are reflected in the revenues and expenses on Mind Medicine's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mind Medicine. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity368 M246.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Mind Medicine is a strong investment it is important to analyze Mind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mind Medicine's future performance. For an informed investment choice regarding Mind Stock, refer to the following important reports:
Check out the analysis of Mind Medicine Correlation against competitors.
For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mind Medicine. If investors know Mind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.71)
Return On Assets
(0.25)
Return On Equity
(0.55)
The market value of Mind Medicine is measured differently than its book value, which is the value of Mind that is recorded on the company's balance sheet. Investors also form their own opinion of Mind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Mind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mind Medicine's market value can be influenced by many factors that don't directly affect Mind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.